| Name | Title | Contact Details |
|---|---|---|
Jillian Thomsen |
CFO | Profile |
Chris Saunders |
Senior Director, Head of R&D Sourcing & Procurement | Profile |
Angeline Tan |
Vice President of R&D QA | Profile |
Anubha Deshpande |
CMO Manager (Biologics) | Profile |
Jonathan Zalevsky |
Chief Research & Development Officer | Profile |
ProNAi Therapeutics is a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform for patients with cancer and hematological diseases. ProNAi`s lead DNAi product candidate, PNT2258, is designed to treat cancers that overexpress BCL2, an important and validated oncogene known to be dysregulated in many types of cancer. ProNAi is pursuing a multi-faceted clinical development strategy designed to efficiently achieve regulatory approval and maximize the commercial opportunity of PNT2258. ProNAi recently initiated "Wolverine", a Phase 2 trial evaluating PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
Teva api is an international pharmaceutical company headquartered in Israel.
Ultimed is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Smile Workshop is dedicated in giving families the services they really care about from their dentist. Pediatrics and accepting Medicaid!
Were one of the world’s leading providers of high quality, empty, hard capsules serving global pharmaceutical and dietary supplement markets.